1 December 2015 in Nuclear Medicine Communications
Objective The blood–brain barrier (BBB) limits the entry of some therapeutics into the brain, resulting in reduced efficacy. BBB-opening techniques have been developed to enhance the entry into the brain. However, a noninvasive, highly sensitive and quantitative method for evaluating the changes in BBB permeability induced by such techniques is needed to optimize treatment protocols. We evaluated 2-amino-[3-11C]isobutyric acid ([3-11C]AIB) as a PET probe to quantify BBB permeability in model rats. Methods BBB opening was induced by a lipopolysaccharide injection or focused ultrasound (FUS) sonication. [3-11C]AIB distribution in the brain was evaluated by autoradiography and PET and compared with that of Evans blue, a traditional BBB permeability marker. Kinetics of [3-11C]AIB was compared with that of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)-enhanced MRI. The unidirectional blood–brain transfer constant (Ki) of [3-11C]AIB was estimated using the Patlak plot. Results [3-11C]AIB uptake in the lesion area was significantly higher than that in the control area and radioactivity colocalized with Evans blue in both models. [3-11C]AIB uptake in the FUS-sonicated region decreased over time after sonication. The ratio of [3-11C]AIB accumulation in the FUS-treated to the contralateral side increased during the experimental period, whereas that of the Gd-DTPA intensity reached a maximum at 10 min after injection and decreased thereafter. The [3-11C]AIB Ki values were significantly higher in the lesion area than the control area. Conclusion [3-11C]AIB PET is a promising, highly sensitive and quantitative imaging method for assessment of BBB permeability.
23 February 2007 in Bioorganic & Medicinal Chemistry
22 October 2018 in Journal of Cerebral Blood Flow & Metabolism
Accumulation of detrimental glutathione-conjugated metabolites in the brain potentially causes neurological disorders, and must therefore be exported from the brain. However, in vivo mechanisms of glutathione-conjugates efflux from the brain remain unknown. We investigated the involvement of transporters in glutathione-conjugates efflux using 6-bromo-7-[ 11 C]methylpurine ([ 11 C]1), which enters the brain and is converted into its glutathione conjugate, S-(7-[ 11 C]methylpurin-6-yl)glutathione ([ 11 C]2). In mice of control and knockout of P-glycoprotein/breast cancer resistance protein and multidrug resistance-associated protein 2 ([ Mrp2] −/− ), [ 11 C]2 formed in the brain was rapidly cleared, with no significant difference in efflux rate. In contrast, [ 11 C]2 formed in the brain of Mrp1 −/− mice was slowly cleared, whereas [ 11 C]2 microinjected into the brain of control and Mrp1 −/− mice was 75% cleared within 60 min, with no significant difference in efflux rate. These suggest that Mrp1 contributes to [ 11 C]2 efflux across cell membranes, but not BBB. Efflux rate of [ 11 C]2 formed in the brain was significantly lower in Mrp4 −/− and organic anion transporter 3 ( Oat3) −/− mice compared with control mice. In conclusion, Mrp1, Oat3, and Mrp4 mediate [ 11 C]2 efflux from the brain. Mrp1 may contribute to [ 11 C]2 efflux from brain parenchymal cells, while extracellular [ 11 C]2 is likely cleared across the BBB, partly by Oat3 and Mrp4.
1 January 2018 in Phytomedicine
6 February 2020 in Journal of Medicinal Chemistry
11 August 2022 in Bioconjugate Chemistry